Endothelin-1 concentrations in pericardial fluid are more elevated in patients with ischemic heart disease than in patients with nonischemic heart disease.

There is epidemiologic evidence that the prognosis of patients with nonischemic heart failure is better than that for patients with ischemic heart failure. In addition, studies have revealed that patients with ischemic heart failure show a poorer response to medical therapy. However, the pathophysiologic difference between ischemic and nonischemic heart disease is unclear. To clarify this point, we measured atrial natriuretic peptide, brain natriuretic peptide, angiotensin II, endothelin (ET)-1. interleukin-1beta interleukin-6. tumor necrosis factor (TNF)-alpha soluble TNF receptor I, and soluble TNF receptor II concentrations in plasma and pericardial fluid in patients with ischemic or nonischemic heart disease undergoing cardiac surgery. The pericardial ET-1 concentration in patients with ischemic heart disease was statistically greater than that in patients with nonischemic heart disease (about 1.5-fold), although no difference was found in the plasma ET-1 concentration. These findings suggest that the production and secretion of ET-1 from the myocardium in patients with ischemic heart disease are augmented to a greater extent than in patients with nonischemic heart disease. This result may lead to a greater understanding of the pathophysiology of ischemic heart disease.

[1]  M. Keating.  Genetic approaches to cardiovascular disease. Supravalvular aortic stenosis, Williams syndrome, and long-QT syndrome. , 1995, Circulation.

[2]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[3]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[4]  S. Vanni,et al.  Cardiac Angiotensin II Formation in the Clinical Course of Heart Failure and Its Relationship With Left Ventricular Function , 2001, Circulation research.

[5]  Mark A. Hlatky,et al.  Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .

[6]  F. Follath,et al.  Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease. , 1999, Journal of cardiovascular pharmacology.

[7]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[8]  M. Yanagisawa,et al.  Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. , 1995, Circulation research.

[9]  M. Yanagisawa,et al.  INCREASED PLASMA CONCENTRATIONS OF ENDOTHELIN-1 AND BIG ENDOTHELIN-1 IN ACUTE MYOCARDIAL INFARCTION , 1989, The Lancet.

[10]  W. Abraham,et al.  Ischemic and nonischemic heart failure do not require different treatment strategies. , 1999, Journal of cardiovascular pharmacology.

[11]  J. Rouleau,et al.  Elevated Endothelin‐1 in Heart Failure and Loss of Normal Response to Postural Change , 1992, Circulation.

[12]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[13]  F. Follath,et al.  Etiology and response to drug treatment in heart failure. , 1998, Journal of the American College of Cardiology.

[14]  C. T. Layton,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia , 1996 .

[15]  S. Vanni,et al.  Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. , 2000, Circulation research.

[16]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[17]  J. McMurray,et al.  Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.

[18]  R. Nohara,et al.  Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. , 1996, Circulation.

[19]  F. Marumo,et al.  Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. , 1996, Journal of molecular and cellular cardiology.

[20]  A. Mebazaa,et al.  Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. , 1997, Circulation research.

[21]  C M O'Connor,et al.  Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[22]  M. Böhm,et al.  Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. , 1999, Circulation.

[23]  ICHAEL,et al.  THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .

[24]  F. Horkay,et al.  Intrapericardial infusion of endothelin-1 induces ventricular arrhythmias in dogs. , 1998, Cardiovascular research.

[25]  Y. Kihara,et al.  Pericardial fluid from patients with ischemic heart disease accelerates the growth of human vascular smooth muscle cells. , 2000, Japanese circulation journal.

[26]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[27]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[28]  F. Marumo,et al.  Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. , 1991, The American journal of cardiology.

[29]  G. Perna,et al.  Regional wall motion analysis by dobutamine stess echocardiography to distinguish between ischemic and nonischemic dilated cardiomyopathy. , 1996, American heart journal.

[30]  F. Horkay,et al.  Characterization of canine pericardial fluid endothelin-1 levels. , 1998, Journal of cardiovascular pharmacology.

[31]  M. Segal,et al.  A study of the composition of pericardial fluid, with special reference to the probable mechanism of fluid formation. , 1978, The Journal of physiology.

[32]  D. Mann,et al.  Expression and functional significance of tumor necrosis factor receptors in human myocardium. , 1995, Circulation.

[33]  M. Mondal,et al.  Effect of vasodilator therapy on mortality in chronic congestive heart failure. , 1993, The Journal of the Association of Physicians of India.

[34]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[35]  M. Entman,et al.  Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. , 1999, Circulation.

[36]  A. Chan,et al.  Effect of cocaine on cardiac biochemical functions. , 1999, Journal of cardiovascular pharmacology.

[37]  C. Holt,et al.  Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.

[38]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[39]  F. Horkay,et al.  Presence of immunoreactive endothelin-1 and atrial natriuretic peptide in human pericardial fluid. , 1997, Life sciences.

[40]  StefanoCorda,et al.  Trophic Effect of Human Pericardial Fluid on Adult Cardiac Myocytes , 1997 .

[41]  Y. Uchida,et al.  Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. , 1995, American heart journal.

[42]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[43]  D. Zipes,et al.  Prostaglandins in the pericardial fluid modulate neural regulation of cardiac electrophysiological properties. , 1990, Circulation research.

[44]  M. Budoff,et al.  Usefulness of electron beam computed tomography scanning for distinguishing ischemic from nonischemic cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[45]  Eter,et al.  EFFECT OF AMLODIPINE ON MORBIDITY AND MORTALITY IN SEVERE CHRONIC HEART FAILURE , 2000 .

[46]  A. Giaid,et al.  Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. , 1998, Journal of cardiovascular pharmacology.

[47]  A. Mebazaa,et al.  Potential paracrine role of the pericardium in the regulation of cardiac function. , 1998, Cardiovascular research.